ProxsysRx’s process for recovering lost 340B savings and revenue
As we’ve noted in multiple earlier blog posts, 340B ESP is nothing short of a blatant, lawless tactic used by scores of drug manufacturers to disallow the discounts they are legally obligated to offer eligible entities. At the same time, a number of additional manufacturers are placing — separate from 340B ESP — similarly-unlawful, and unnecessary, reporting burdens on hospitals submitting claims for 340B savings.
A brief history of 340B-related manufacturer restrictions.
The drug manufacturing industry first implemented 340B restrictions with the June, 2020 launch of 340B ESP — an online portal operated by Second Sight Solutions, which is a privately owned corporation created and run by a man with a long history of drug-industry advocacy. According to HRSA, the site has no legal right to impose its restrictions on covered entities. Read More >>
